SAN
DIEGO, Nov. 9, 2022 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that
members of its management team are scheduled to present and host
investor meetings at the following investor conferences:
Event:
|
|
|
|
J.P. Morgan Equity
Opportunities Forum
|
Participant:
|
|
|
|
Dr. Helen Torley,
President and Chief Executive Officer
|
Format:
|
|
|
|
1x1 Meetings
|
Date:
|
|
|
|
Tuesday, November 15,
2022
|
Location:
|
|
|
|
Miami, FL
|
|
|
|
|
|
Event:
|
|
|
|
Piper Sandler 34th
Annual Health Conference
|
Participant:
|
|
|
|
Dr. Helen Torley,
President and Chief Executive Officer
|
Format:
|
|
|
|
Fireside Chat and 1x1
Meetings
|
Presentation
Date:
|
|
|
|
Wednesday, November 30,
2022
|
Presentation
Time:
|
|
|
|
7:00 a.m. PT / 10:00
a.m. ET
|
Location:
|
|
|
|
New York, NY
|
Event:
|
5th Annual Evercore IS
HealthCONx Conference
|
Participant:
|
Nicole LaBrosse, Chief
Financial Officer
|
Format:
|
Fireside Chat and 1x1
Meetings
|
Presentation
Date:
|
Thursday, December 1,
2022
|
Presentation
Time:
|
8:20 a.m. PT / 11:20
a.m. ET
|
Location:
|
Virtual
|
Live audio webcasts of the Piper Sandler and Evercore fireside
chats will be available on the Investor Relations
section of the Company's website. Replays of the audio
webcasts will be available for 90 days following the
conference.
About Halozyme Therapeutics,
Inc.
Halozyme is a biopharmaceutical company bringing disruptive
solutions to significantly improve patient experiences and outcomes
for emerging and established therapies. As the innovators of the
ENHANZE® technology with the proprietary enzyme rHuPH20, Halozyme's
commercially-validated solution is used to facilitate the delivery
of injected drugs and fluids in order to reduce the treatment
burden to patients. Having touched more than 600,000 patient lives
in post-marketing use in five commercialized products across more
than 100 global markets, Halozyme has licensed its ENHANZE®
technology to leading pharmaceutical and biotechnology companies
including Roche, Takeda, Pfizer, AbbVie, Eli Lilly, Bristol-Myers
Squibb, Alexion, argenx, Horizon Therapeutics, ViiV Healthcare and
Chugai Pharmaceutical.
Halozyme also develops, manufactures and commercializes, for
itself or with partners, drug-device combination products using its
advanced auto-injector technology that are designed to provide
commercial or functional advantages such as improved convenience
and tolerability, and enhanced patient comfort and adherence. The
Company has a commercial portfolio of proprietary products
including XYOSTED®, TLANDO® and NOCDURNA® and partnered commercial
products and ongoing product development programs with several
pharmaceutical companies including Teva Pharmaceutical, Covis
Pharma, Pfizer and Idorsia Pharmaceuticals.
Halozyme is headquartered in San
Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations
facility.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-359-3016
tbui@antarespharma.com
Dawn Schottlandt / Claudia Styslinger
Argot Partners
212-600-1902
Halozyme@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/halozyme-to-participate-in-upcoming-investor-conferences-301672612.html
SOURCE Halozyme Therapeutics, Inc.